Marshall Wace North America’s Madrigal Pharmaceuticals MDGL Stock Holding History

Marshall Wace North America’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$501K	Sell	6,274 -89,106	-93%	-$7.7M	﹤0.01%	1125
2021 Q2	$9.29M	Buy	+95,380	New	+$11.3M	0.04%	390
2020 Q2	–	Sell	-154	Closed	-$10K	–	1340
2020 Q1	$10K	Buy	+154	New	+$12.8K	﹤0.01%	1162
2019 Q2	–	Sell	-141,301	Closed	-$17.7M	–	1412
2019 Q1	$17.7M	Buy	+141,301	New	+$17.6M	0.13%	157
2018 Q3	–	Sell	-34,985	Closed	-$9.79M	–	1186
2018 Q2	$9.79M	Buy	+34,985	New	+$6.14M	0.06%	341
2018 Q1	–	Sell	-45,785	Closed	-$4.2M	–	1584
2017 Q4	$4.2M	Buy	+45,785	New	+$2.62M	0.02%	634

Other funds holding MDGL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Marshall Wace North America's MDGL Position: Q3 2021 in Review

Marshall Wace North America reduced its Madrigal Pharmaceuticals (MDGL) stake by 93% in Q3 2021, selling an estimated $7.7M and leaving 6,274 shares worth $501K. The position accounts for ﹤0.01% of the portfolio, ranked #1125.

Marshall Wace North America first reported a position in MDGL in Q4 2017 and has held it in 6 quarters since. The position peaked at $17.7M in Q1 2019. 133 funds tracked by Wall St. Rank hold MDGL as of Q3 2021.

Marshall Wace North America held 6,274 shares of Madrigal Pharmaceuticals worth $501K as of Q3 2021.
Marshall Wace North America sold 89,106 Madrigal Pharmaceuticals shares in Q3 2021, an estimated $7.7M.
Madrigal Pharmaceuticals made up ﹤0.01% of Marshall Wace North America's portfolio in Q3 2021, its #1125 holding.
Marshall Wace North America first reported a position in Madrigal Pharmaceuticals in Q4 2017 and has held it in 6 quarters since.
Marshall Wace North America's Madrigal Pharmaceuticals position peaked at $17.7M in Q1 2019.
133 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q3 2021.

Based on Marshall Wace North America's 13F filing for Q3 2021, filed 15 Nov 2021.